Skip to main content

Asuragen Licenses BRAF V600E Mutation for Cancer Testing


Asuragen said this week that it has taken a non-exclusive license to the BRAF V600E mutation from Johns Hopkins University for use in its CLIA laboratory for clinical research and patient testing for a range of cancers.

The presence of the V600E mutation in the BRAF oncogene has been shown to impact prognosis and the prediction of therapeutic response in colorectal cancer and also predicts a poorer prognosis in thyroid cancer, Asuragen said.

The company has integrated the BRAF mutation into its Luminex-based Signature KRAS Mutations assay for research use, and also plans to offer BRAF mutation testing in its services laboratory for clinical trials and companion diagnostics studies.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.